Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

依维莫司 奥曲肽 脑膜瘤 医学 相(物质) 内科学 肿瘤科 放射科 物理 生长抑素 量子力学
作者
Thomas Graillon,Marc Sanson,Chantal Campello,Ahmed Idbaïh,Matthieu Peyre,Hadrien Peyrière,Noémie Basset,Didier Autran,Catherine Roche‐Lestienne,M. Kalamaridès,Pierre‐Hugues Roche,S. Fuentès,Émeline Tabouret,Maryline Barrié,Anita Cohen,Mohamed Boucékine,Mohamed Boucékine,Karine Baumstarck,Dominique Figarella‐Branger,Anne Barlier,H. Dufour,Olivier Chinot
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:26 (3): 552-557 被引量:102
标识
DOI:10.1158/1078-0432.ccr-19-2109
摘要

Aggressive meningiomas that progress after surgery/radiotherapy represent an unmet medical need. Strong and constant expression of SSTR2A receptors and activation of the Pi3K/Akt/mTOR pathway have been demonstrated in meningiomas. The combination of everolimus, an mTOR inhibitor, and octreotide, a somatostatin agonist, has shown additive antitumor effect in vitro. The phase II CEVOREM trial investigated the efficacy of this combination on recurrent meningiomas.Patients with documented recurrent tumor progression ineligible for further surgery/radiotherapy were eligible to receive octreotide (30 mg/d, day 1) and everolimus (10 mg/d, days 1-28). The primary endpoint was the 6-month progression-free survival rate (PFS6). The secondary endpoints were overall survival, response rate, tumor growth rate according to central review, and safety.A total of 20 patients were enrolled, including 2 with World Health Organization (WHO) grade I tumors, 10 with WHO grade II tumors, and 8 with WHO grade III tumors; furthermore, 4 patients harbored NF2 germline mutation. The overall PFS6 was 55% [95% confidence interval (CI), 31.3%-73.5%], and overall 6- and 12-month survival rates were 90% (95% CI, 65.6%-97.4%) and 75% (95% CI, 50.0%-88.7%), respectively. A major decrease (>50%) was observed in the growth rate at 3 months in 78% of tumors. The median tumor growth rate decreased from 16.6%/3 months before inclusion to 0.02%/3 months at 3 months (P < 0.0002) and 0.48%/3 months at 6 months after treatment (P < 0.0003).The combination of everolimus and octreotide was associated with clinical and radiological activity in aggressive meningiomas and warrants further studies. Decrease in the tumor volume growth rate should be considered a complementary and sensitive endpoint to select potentially effective drugs for recurrent meningiomas.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
离开时是天命完成签到,获得积分10
刚刚
小二郎应助wu61采纳,获得10
刚刚
GH发布了新的文献求助10
刚刚
azure完成签到,获得积分10
4秒前
wenbinvan完成签到,获得积分0
4秒前
4秒前
企鹅嗷嗷完成签到 ,获得积分10
6秒前
MrT完成签到 ,获得积分10
6秒前
6秒前
wpybird完成签到,获得积分10
8秒前
踏实天磊完成签到 ,获得积分10
8秒前
lily完成签到,获得积分10
9秒前
lixia完成签到 ,获得积分10
11秒前
bjr完成签到 ,获得积分10
11秒前
Yang22完成签到,获得积分10
12秒前
12秒前
yt完成签到,获得积分10
14秒前
伍寒烟完成签到,获得积分10
15秒前
梦夜孤星完成签到 ,获得积分10
16秒前
完美世界应助Archie采纳,获得10
16秒前
凌寻绿完成签到,获得积分10
16秒前
细嗅蔷薇完成签到,获得积分10
18秒前
胡杨完成签到,获得积分10
21秒前
可乐SAMA完成签到,获得积分10
23秒前
lj完成签到 ,获得积分10
25秒前
岁月如酒完成签到,获得积分10
26秒前
潇洒的书文完成签到,获得积分10
27秒前
29秒前
9℃完成签到 ,获得积分10
30秒前
嘟嘟豆806完成签到 ,获得积分10
31秒前
猫咪也疯狂应助苏满天采纳,获得10
32秒前
星宇完成签到 ,获得积分10
32秒前
谭久久完成签到,获得积分20
32秒前
今夜不设防完成签到,获得积分10
33秒前
李ye发布了新的文献求助10
33秒前
lj关注了科研通微信公众号
33秒前
菜菜完成签到 ,获得积分10
35秒前
博学而多问完成签到 ,获得积分10
38秒前
白茶的雪完成签到,获得积分10
40秒前
40秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3099821
求助须知:如何正确求助?哪些是违规求助? 2751309
关于积分的说明 7612489
捐赠科研通 2403104
什么是DOI,文献DOI怎么找? 1275188
科研通“疑难数据库(出版商)”最低求助积分说明 616293
版权声明 599053